This morning, Forest Laboratories, Inc. (FRX), reported earnings per share of 85 cents for the second quarter of fiscal 2010, in-line with the Zacks Consensus Estimate. Product sales increased 4% to $962.7 million. Although Lexapro sales declined 3.1% to $566 million, Namenda, which is approved for the treatment of moderate and severe Alzheimer’s disease, delivered sales of $275.3 million, recording a growth of 11.9% from the year-ago period. Improved patient access and increased promotional efforts should help keep Namenda sales strong. Bystolic, Forest’s beta-blocker for the treatment of hypertension, posted sales of $40.7 million. This was significantly higher than the year ago sales of $14.2 million. Contract revenue, consisting primarily of Benicar co-promotion income, increased 7.2% to $50.6 million. Forest’s most recent product launch, Savella, which is approved for the management of fibromyalgia, posted sales of $10.2 million. The product, which has been developed in ...

We are presenting a list of companies which we believe are currently mispriced, based on our estimate of fair value, by the market. We develop our fair value ranges by projected free cash flow out one year and estimating an appropriate FCF multiple based on our assessment of risk and the strength of the balance sheet.

Cisco Systems [CSCO: 19.57, +0.84 (+4.48%)] Recent Price $17.04 Value Range 21.86 – $38.41 Cisco Systems, Inc. designs, manufactures and sells Internet protocol (IP)-based networking and other products related to the communications and information technology (IT) industry, and provides services associated with these products and their use. The Company provides a line of products for transporting data, voice, and video within buildings, across campuses, and around the world. Its products are designed to transform how people connect, communicate and collaborate. Cisco Systems, Inc.’s products, which include primarily routers, switches, and products that the

...

For Immediate Release

Chicago, IL - June 18, 2009 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Apple (AAPL), Integrated Device Technology (IDTI), Leadis Technology (LDIS), Forest Laboratories, Inc. (FRX) and FedEx Corporation (FDX).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Wednesday's Analyst Blog:

Touch-Screens Feeling Hot

This technology seemed to struggle to gain acceptance until Apple (AAPL) released the iPhone.

The capacitive touch-screen and touch-button controller segment is projected to hit 1.3 billion units by 2012, a 44 percent compounded annual growth rate, according to

...

Reiterating Hold Recommendation on Forest LabsForest Laboratories, Inc. (FRX) turned in a very solid fiscal 2008. While 3rd quarter revenue was below our forecast, EPS was significantly better due to stronger operating margins as a result of better-than-expected gross margins and lower R&D and SG&A expenses. Revenue came in about $11 million shy of our expectations due to lower than forecast sales of Lexapro. We expect Lexapro sales to show a modest improvement now with the adolescent indication added to the label.Management's guidance for the full fiscal year remains below results in 2008, but has been revised upwards for the 3rd time. Forest now expects full-year adjusted EPS in the range of $3.35 - $3.45. The guidance reflects lower R&D expenses in the current quarter relative to previous expectations.We expect higher SG&A expenses through the remainder of the year to support the ...